Theramutein modultors
AssigneeHMI Medical Innovations, LLC
InventorGerard M. Housey
Life of this patent
Estimating the term…
Abstract
This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.
Claims21
A method for identifying and obtaining an inhibitor or activator of a theramutein from a first collection of compounds, wherein the theramutein is capable of eliciting a detectable phenoresponse and the theramutein has a corresponding prototheramutein, the method comprising:
- (a) identifying a first subset of the first collection of compounds, the first subset of compounds comprising compounds that affect growth of a cell expressing the theramutein,
- (b) rank ordering a second subset of the first subset of compounds into a rank-ordered list, the compounds of the second subset of compounds being rank-ordered based on their ability to affect growth of a cell expressing the theramutein;
- (c) testing individual compounds of the second subset of compounds by comparing
- (i) the phenoresponse obtained when contacting an individual compound with a respective test cell expressing the theramutein with
- (ii) the phenoresponse obtained when contacting the individual compound with a control cell expressing the prototheramutein;
- and
- (d) identifying a compound of the second subset of compounds as an inhibitor or activator of the theramutein based on results obtained in step (c).
A method for preparing a pharmaceutical composition for treating a theramutein, wherein the theramutein is capable of eliciting a detectable phenoresponse in a cell and the theramutein has a corresponding prototheramutein, the method comprising:
- (a) testing a compound by comparing
- (i) the phenoresponse obtained when contacting the compound with a respective test cell expressing the theramutein with
- (ii) the phenoresponse obtained when contacting the compound with a control cell expressing the prototheramutein;
- (b) identifying the compound as an inhibitor or activator of the theramutein based on results obtained in step (a);
- and
- (c) formulating the identified compound into a pharmaceutically acceptable composition.
Dependencies are inferred from the claim text.